Injectable Antibodies: Products, Markets, Players and Forecasts
NEW YORK, July 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Injectable Antibodies: Products, Markets, Players and Forecasts
http://www.reportlinker.com/p0864024/Injectable-Antibodies-Products-Markets-Players-and-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
The administration of therapeutic antibodies via injection is becoming an increasingly important healthcare treatment method for a growing number diseases and indications having broad implications for patient health and well-being. The inherent instability of protein drugs has led to a number of challenges as the developers of injectable antibodies attempt to deal with packaging, handling, reconstitution and drug administration issues. These challenges are being compounded by the trend to patient self-medication, as population demographics and efforts by managed care providers to control healthcare costs drive the growth in drug self-administration, particularly for chronic conditions. This trend is introducing a new class of naïve users to parenteral drug delivery. This report analyzes twenty-six injectable/Infusible therapeutic antibody drugs and examines key packaging, dosing, regulatory, economic and competitive factors that represent opportunities, risk factors and potential barriers to commercial success.
Highlights
· Provides detailed analysis of injectable antibody market segments, market dynamics and market demographics
· Analyzes products, therapeutic demand drivers and evaluates commercial drug products in more than two dozen injectable antibodies
· Analyzes technologies and market development issues for injectable antibodies
· Provides market data and forecasts to 2016
· Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
Summary of Contents
Executive Summary
Antibody Therapeutics Market Dynamics
The Antibody Therapeutics Marketspace
Clinical Trials and Drug Approvals
The Competitive Landscape
Demographics, Managed Care and Growth
Risks and Opportunities
Formulating Antibody Drugs
Formulation Strategies
Antibody Formulation Technologies
Antibody Packaging & Delivery
Antibody Drug Distribution Strategies
Injectable Antibodies – Indications and Therapeutic Markets
Asthma
Infectious Disease
Oncology
Autoimmunity
Osteoporosis
Macular Degeneration
Injectable Antibody Drug Product Assessments and Forecasts
Adalimumab (Humira)
Alefacept (Amevive)
Alemtuzumab (Campath)
Belimumab (Benlysta)
Bevacizumab (Avastin)
Brentuximab vedotin (Adcetris)
Canakinumab (Ilaris)
Certolizumab (Cimzia)
Cetuximab (Erbitux)
Denosumab (Prolia)
Eculizumab (Soliris)
Gemtuzumab (Mylotarg)
Golimumab (Simponi)
Ibritumomab (Zevalin)
Infliximab (Remicade)
Natalizumab (Tysabri)
Ofatumumab (Arzerra)
Palivizumab (Synagis)
Panitumumab (Vectibix)
Omalizumab (Zolair)
Ranibizumab (Lucentis)
Rituximab (Rituxin)
Tocilizumab (Actemra)
Tositumomab (Bexxar)
Trastuzumab (Herceptin)
Ustekinumab (Stelara)
Market Factors
Regulatory Issues
Patient Compliance
Healthcare Economics
Company Profiles
To order this report:
Biopharmaceutical Industry: Injectable Antibodies: Products, Markets, Players and Forecasts
Check our Industry Analysis and Insights
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article